hyperOligos
Pre-clinical- Indications
- Acute Myeloid Leukemia, Cancer
Company intelligence / Profile preview
Core Biotherapeutics
Ladera Ranch, California, USAprnewswire.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Preclinical
01
Overview
Core Biotherapeutics is developing a platform to identify and target transcription factor networks that drive diseases. They received an SBIR Phase I award in 2025 to determine mechanisms driving diseases at the molecular network level.
- Therapeutic areas
- OncologyCardiovascularNeurologyRheumatology
- Modalities
- Oligonucleotide-based drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Colorado Anschutz Medical Campus (CU Anschutz)CU InnovationsJordan Lab
Beyond the preview
Go deeper on Core Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Core Biotherapeutics.